Albany Molecular Research (AMRI) Reports Q4 Loss of $0.19; Guides Contract Revs
Tweet
Share
E-mailGet Alerts AMRI Hot Sheet
Price: $21.74 --0%
Financial Fact:
Cost of contract revenue: 123.49M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Cost of contract revenue: 123.49M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Albany Molecular Research (NASDAQ: AMRI) reported Q4 EPS of ($0.19), versus ($0.16) reported last year. Revenue for the quarter came in at $46.6 million, versus $48.6 million reported last year.
Sees Q1 2012 contract revenue of $37-$40 million.
Sees FY2012 contract revenue of $176-$186 million.
For earnings history and earnings-related data on Albany Molecular Research (AMRI) click here.
Sees Q1 2012 contract revenue of $37-$40 million.
Sees FY2012 contract revenue of $176-$186 million.
For earnings history and earnings-related data on Albany Molecular Research (AMRI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- BMO starts chip stocks coverage: Here are its preferred picks
- Investing.com’s stocks of the week
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
